Skip to main content
Erschienen in: International Journal of Hematology 1/2015

01.07.2015 | Case Report

Pseudo-Pelger–Huët anomaly and granulocytic dysplasia associated with human granulocytic anaplasmosis

verfasst von: Sunyoung Lee, Pouya Khankhanian, Carlos Salama, Maritza Brown, Joseph Lieber

Erschienen in: International Journal of Hematology | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Pseudo-Pelger–Huët anomaly (PHA) refers to mono- or bi-lobed granulocytes, reportedly observed in patients with severe infections and inflammation or hematological malignancies including myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Dysplastic changes in granulocytes are typical manifestations in MDS and granulocytic leukemias. Here, we report the unique case of a patient found to have human granulocytic anaplasmosis (HGA), a tick-borne disease caused by Anaplasma phagocytophilum, a Gram-negative coccobacillus. This patient showed striking hematological manifestations including a large number of pseudo-PHA, a severe degree of left shift, and dysplastic granulocytes. These hematological presentations on the peripheral smear all resolved with doxycycline treatment, implying that the changes were most likely reactive manifestations secondary to HGA, rather than underlying hematological malignancies such as MDS or AML.
Literatur
1.
Zurück zum Zitat Cunningham JM, Patnaik MM, Hammerschmidt DE, Vercellotti GM. Historical perspective and clinical implications of the Pelger-Huet cell. Am J Hematol. 2009;84:116–9.PubMedCrossRef Cunningham JM, Patnaik MM, Hammerschmidt DE, Vercellotti GM. Historical perspective and clinical implications of the Pelger-Huet cell. Am J Hematol. 2009;84:116–9.PubMedCrossRef
2.
Zurück zum Zitat Dechat T, Pfleghaar K, Sengupta K, et al. Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev. 2008;22:832–53.PubMedCentralPubMedCrossRef Dechat T, Pfleghaar K, Sengupta K, et al. Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev. 2008;22:832–53.PubMedCentralPubMedCrossRef
3.
Zurück zum Zitat Hoffmann K, Dreger CK, Olins AL, et al. Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger–Huet anomaly). Nat Genet. 2002;31:410–4.PubMed Hoffmann K, Dreger CK, Olins AL, et al. Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger–Huet anomaly). Nat Genet. 2002;31:410–4.PubMed
4.
Zurück zum Zitat Best S, Salvati F, Kallo J, et al. Lamin B-receptor mutations in Pelger–Huët anomaly. Br J Haematol. 2003;123:542–4.PubMedCrossRef Best S, Salvati F, Kallo J, et al. Lamin B-receptor mutations in Pelger–Huët anomaly. Br J Haematol. 2003;123:542–4.PubMedCrossRef
5.
Zurück zum Zitat Economopoulou C, Pappa V, Kontsioti F, et al. Analysis of apoptosis regulatory gene expression in the bone marrow (BM) of adult de novo myelodysplastic syndromes (MDS). Leuk Res. 2008;32:61–9.PubMedCrossRef Economopoulou C, Pappa V, Kontsioti F, et al. Analysis of apoptosis regulatory gene expression in the bone marrow (BM) of adult de novo myelodysplastic syndromes (MDS). Leuk Res. 2008;32:61–9.PubMedCrossRef
6.
Zurück zum Zitat Soenen V, Preudhomme C, Roumier C, et al. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood. 1998;91:1008–15.PubMed Soenen V, Preudhomme C, Roumier C, et al. 17p Deletion in acute myeloid leukemia and myelodysplastic syndrome. Analysis of breakpoints and deleted segments by fluorescence in situ. Blood. 1998;91:1008–15.PubMed
7.
Zurück zum Zitat Kuriyama K, Tomonaga M, Matsuo T, et al. Diagnostic significance of detecting pseudo-Pelger-Huet anomalies and micro-megakaryocytes in myelodysplastic syndrome. Br J Haematol. 1986;63:665–9.PubMedCrossRef Kuriyama K, Tomonaga M, Matsuo T, et al. Diagnostic significance of detecting pseudo-Pelger-Huet anomalies and micro-megakaryocytes in myelodysplastic syndrome. Br J Haematol. 1986;63:665–9.PubMedCrossRef
8.
Zurück zum Zitat Fugazza G, Bruzzone R, Puppo L, Sessarego M. Granulocytes with segmented nucleus retain normal chromosomes 17 in Philadelphia chromosome-positive chronic myeloid leukemia with i(17q) and pseudo-Pelger anomaly: a case report studied with fluorescence in situ hybridization. Cancer Genet Cytolgenet. 1996;90:166–70.CrossRef Fugazza G, Bruzzone R, Puppo L, Sessarego M. Granulocytes with segmented nucleus retain normal chromosomes 17 in Philadelphia chromosome-positive chronic myeloid leukemia with i(17q) and pseudo-Pelger anomaly: a case report studied with fluorescence in situ hybridization. Cancer Genet Cytolgenet. 1996;90:166–70.CrossRef
9.
Zurück zum Zitat Asmis LM, Hadaya K, Majno P, et al. Acquired and reversible Pelger–Huët anomaly of polymorphonuclear neutrophils in three transplant patients receiving mycophenolate mofetil therapy. Am J Hematol. 2003;73:244–8.PubMedCrossRef Asmis LM, Hadaya K, Majno P, et al. Acquired and reversible Pelger–Huët anomaly of polymorphonuclear neutrophils in three transplant patients receiving mycophenolate mofetil therapy. Am J Hematol. 2003;73:244–8.PubMedCrossRef
10.
Zurück zum Zitat Kennedy GA, Kay TD, Johnson DW, et al. Neutrophil dysplasia characterised by a pseudo-Pelger-Huet anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases. Pathology. 2002;34:263–6.PubMedCrossRef Kennedy GA, Kay TD, Johnson DW, et al. Neutrophil dysplasia characterised by a pseudo-Pelger-Huet anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases. Pathology. 2002;34:263–6.PubMedCrossRef
11.
Zurück zum Zitat Dusse LM, Moreira AM, Vieira LM, et al. Acquired Pelger–Huët: what does it really mean. Clin Chim Acta. 2010;411:1587–90.PubMedCrossRef Dusse LM, Moreira AM, Vieira LM, et al. Acquired Pelger–Huët: what does it really mean. Clin Chim Acta. 2010;411:1587–90.PubMedCrossRef
12.
Zurück zum Zitat Bakken JS, Dumler JS, Chen SM, et al. Human granulocytic ehrlichiosis in the upper Midwest United States: a new species emerging. JAMA. 1994;272:212–8.PubMedCrossRef Bakken JS, Dumler JS, Chen SM, et al. Human granulocytic ehrlichiosis in the upper Midwest United States: a new species emerging. JAMA. 1994;272:212–8.PubMedCrossRef
13.
Zurück zum Zitat McQuiston JH, McCall CL, Nicholson WL. Ehrlichiosis and related infections. J Am Vet Med Assoc. 2003;223:1750–6.PubMedCrossRef McQuiston JH, McCall CL, Nicholson WL. Ehrlichiosis and related infections. J Am Vet Med Assoc. 2003;223:1750–6.PubMedCrossRef
14.
Zurück zum Zitat Carlyon JA, Fikrig E. Mechanisms of evasion of neutrophil killing by Anaplasma phagocytophilum. Curr Opin Hematol. 2006;13:28–33.PubMedCrossRef Carlyon JA, Fikrig E. Mechanisms of evasion of neutrophil killing by Anaplasma phagocytophilum. Curr Opin Hematol. 2006;13:28–33.PubMedCrossRef
15.
Zurück zum Zitat Bakken JS, Dumler S. Human granulocytic anaplasmosis. Infect Dis Clin North Am. 2008;22:433–48.PubMedCrossRef Bakken JS, Dumler S. Human granulocytic anaplasmosis. Infect Dis Clin North Am. 2008;22:433–48.PubMedCrossRef
16.
Zurück zum Zitat Cadman HF, Kelly PJ, Matthewman LA, et al. Comparison of the dot-blot enzyme linked immunoassay with immunofluorescence for detecting antibodies to Ehrlichia canis. Vet Rec. 1994;135:362.PubMedCrossRef Cadman HF, Kelly PJ, Matthewman LA, et al. Comparison of the dot-blot enzyme linked immunoassay with immunofluorescence for detecting antibodies to Ehrlichia canis. Vet Rec. 1994;135:362.PubMedCrossRef
17.
Zurück zum Zitat Rotondano TE, de Almeida AM, Lustosa EM, et al. An assessment of whole blood and fractions by nested PCR as a DNA source for diagnosing canine ehrlichiosis and anaplasmosis. Sci World J. 2012;2012:605743.CrossRef Rotondano TE, de Almeida AM, Lustosa EM, et al. An assessment of whole blood and fractions by nested PCR as a DNA source for diagnosing canine ehrlichiosis and anaplasmosis. Sci World J. 2012;2012:605743.CrossRef
18.
Zurück zum Zitat Bakken JS, Aguero-Rosenfeld ME, Tilden RL, et al. Serial measurements of hematologic counts during the active phase of human granulocytic ehrlichiosis. Clin Infect Dis. 2001;32:862–70.PubMedCrossRef Bakken JS, Aguero-Rosenfeld ME, Tilden RL, et al. Serial measurements of hematologic counts during the active phase of human granulocytic ehrlichiosis. Clin Infect Dis. 2001;32:862–70.PubMedCrossRef
19.
Zurück zum Zitat Lepidi H, Bunnell JE, Martin ME, et al. Comparative pathology, and immunohistology associated with clinical illness after Ehrlichia phagocytophila-group infections. Am J Trop Med Hyg. 2000;62:29–37.PubMed Lepidi H, Bunnell JE, Martin ME, et al. Comparative pathology, and immunohistology associated with clinical illness after Ehrlichia phagocytophila-group infections. Am J Trop Med Hyg. 2000;62:29–37.PubMed
20.
Zurück zum Zitat Martin ME, Caspersen K, Dumler JS. Immunopathology and ehrlichial propagation are regulated by interferon-γ and interleukin-10 in a murine model of human granulocytic ehrlichiosis. Am J Pathol. 2001;158:1881–8.PubMedCentralPubMedCrossRef Martin ME, Caspersen K, Dumler JS. Immunopathology and ehrlichial propagation are regulated by interferon-γ and interleukin-10 in a murine model of human granulocytic ehrlichiosis. Am J Pathol. 2001;158:1881–8.PubMedCentralPubMedCrossRef
21.
22.
Zurück zum Zitat Colella R, Hollensead SC. Understanding and recognizing the Pelger–Huët anomaly. Am J Clin Pathol. 2012;137:358–66.PubMedCrossRef Colella R, Hollensead SC. Understanding and recognizing the Pelger–Huët anomaly. Am J Clin Pathol. 2012;137:358–66.PubMedCrossRef
23.
Zurück zum Zitat Klion AD, Law MA, Riemenschneider W, et al. Familial eosinophilia: a benign disorder. Blood. 2004;103:4050–5.PubMedCrossRef Klion AD, Law MA, Riemenschneider W, et al. Familial eosinophilia: a benign disorder. Blood. 2004;103:4050–5.PubMedCrossRef
24.
Zurück zum Zitat Weil SC, Hrisinko MA. A hybrid eosinophilic-basophilic granulocyte in chronic granulocytic leukemia. Am J Clin Pathol. 1987;87:66–70.PubMed Weil SC, Hrisinko MA. A hybrid eosinophilic-basophilic granulocyte in chronic granulocytic leukemia. Am J Clin Pathol. 1987;87:66–70.PubMed
25.
Zurück zum Zitat Fradera J. Erythroid karyorrhexis in myelodysplasia: bone marrow aspirate. Blood. 2008;112:479. Fradera J. Erythroid karyorrhexis in myelodysplasia: bone marrow aspirate. Blood. 2008;112:479.
Metadaten
Titel
Pseudo-Pelger–Huët anomaly and granulocytic dysplasia associated with human granulocytic anaplasmosis
verfasst von
Sunyoung Lee
Pouya Khankhanian
Carlos Salama
Maritza Brown
Joseph Lieber
Publikationsdatum
01.07.2015
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 1/2015
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-015-1769-1

Weitere Artikel der Ausgabe 1/2015

International Journal of Hematology 1/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.